

28 September 2006

**For further information  
please contact:**

Joern Aldag  
President &  
Chief Executive Officer

+49.(0)40.560 81-242  
+49.(0)40.560 81-333 Fax  
joern.aldag@evotec.com

Anne Hennecke  
Director,  
Investor Relations &  
Corporate Communications

+49.(0)40.560 81-286  
+49.(0)40.560 81-333 Fax  
anne.hennecke@evotec.com

Evotec AG  
Schnackenburgallee 114  
22525 Hamburg  
Germany  
www.evotec.com

## **Evotec Achieves Certificate of GMP Compliance from MHRA**

**Hamburg, Germany | Oxford, UK** – Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) today announced it has received a Certificate of GMP Compliance from the Medicines and Healthcare Products Regulatory Agency (MHRA). This replaces the old statement of cGMP compliance previously issued.

**Dr Mario Polywka, Chief Operating Officer at Evotec, said:** “It is gratifying to receive validation of our high quality process development, manufacturing, analytical and quality assurance capabilities through this certification. We are proud to be one of the first companies to receive the new MHRA certificate in place of the old statement of compliance. This certificate means we continue to provide our customers with the best possible facilities and processes to manufacture their drug compounds. I would like to thank our fantastic Quality Department for maintaining such high standards.”

### **About Evotec AG**

Evotec is a leader in the discovery and development of novel small molecule drugs. Both through its own discovery programmes and through contract research partnerships, the Company is generating the highest quality research results to its partners in the pharmaceutical and biotechnology industries.

In proprietary projects, Evotec specialises in finding new treatments for diseases of the Central Nervous System. Evotec has two programmes in clinical development: EVT 201, a partial positive allosteric modulator (pPAM) of the GABA<sub>A</sub> receptor complex for the treatment of insomnia, and EVT 101, a subtype selective NMDA receptor antagonist for the treatment of Alzheimer's disease and/or neuropathic pain.

In contract research, Evotec has established itself as the partner of choice for pharmaceutical and biotechnology companies worldwide. The Company provides innovative and often integrated solutions from drug target to clinic through an unmatched range of capabilities, including early stage assay development and screening through to medicinal chemistry and drug manufacturing.

In 2005, Evotec has generated sales of EUR 80 million with 600 employees located in Hamburg, Germany and near Oxford and in Glasgow, UK.

www.evotec.com